NO20051170L - Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier - Google Patents

Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier

Info

Publication number
NO20051170L
NO20051170L NO20051170A NO20051170A NO20051170L NO 20051170 L NO20051170 L NO 20051170L NO 20051170 A NO20051170 A NO 20051170A NO 20051170 A NO20051170 A NO 20051170A NO 20051170 L NO20051170 L NO 20051170L
Authority
NO
Norway
Prior art keywords
erb
kinase inhibitors
therapeutic combinations
neoplastic therapies
neoplastic
Prior art date
Application number
NO20051170A
Other languages
English (en)
Inventor
David William Fry
William Leon Elliott
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20051170L publication Critical patent/NO20051170L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Administrering av en irreversibel tyroskinkinasehemmer slik som C1-1033 i kombinasjon med et eller flere andre anti-neoplastiske midler eller ioniserende stråling er synergistisk for å behandle kreft.
NO20051170A 2002-08-07 2005-03-04 Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier NO20051170L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11
PCT/IB2003/003388 WO2004014386A1 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Publications (1)

Publication Number Publication Date
NO20051170L true NO20051170L (no) 2005-05-06

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051170A NO20051170L (no) 2002-08-07 2005-03-04 Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier

Country Status (17)

Country Link
US (2) US20040067942A1 (no)
EP (1) EP1549320A1 (no)
JP (1) JP2005538129A (no)
CN (1) CN1674908A (no)
AR (1) AR040792A1 (no)
AU (1) AU2003249450A1 (no)
BR (1) BR0313470A (no)
CA (1) CA2494270A1 (no)
IL (1) IL166423A0 (no)
MX (1) MXPA05001430A (no)
NO (1) NO20051170L (no)
PA (1) PA8578001A1 (no)
PE (1) PE20040990A1 (no)
PL (1) PL375414A1 (no)
RU (1) RU2005102836A (no)
TW (1) TW200404532A (no)
WO (1) WO2004014386A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) * 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
NZ551355A (en) * 2004-06-03 2009-09-25 Hoffmann La Roche Treatment of cancer with irinotecan (CPT-11) and erlotinib
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
RU2006146619A (ru) * 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
US20090317383A1 (en) * 2004-06-04 2009-12-24 Berger Mark S Cancer treatment method
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2217227B1 (en) * 2007-11-12 2013-08-21 BiPar Sciences, Inc. Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
AU2012253858B2 (en) * 2011-05-06 2014-05-08 Merrimack Pharmaceuticals, Inc. Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-ErbB3 agents
US20210275518A1 (en) * 2020-03-06 2021-09-09 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
CZ20031927A3 (cs) * 2001-01-09 2003-10-15 Merck Patent Gmbh Farmaceutický prostředek na bázi inhibitorů receptoru tyrosinkinázy a inhibitorů angiogeneze

Also Published As

Publication number Publication date
US20060293323A1 (en) 2006-12-28
PE20040990A1 (es) 2004-12-27
CA2494270A1 (en) 2004-02-19
AU2003249450A1 (en) 2004-02-25
PA8578001A1 (es) 2004-05-07
IL166423A0 (en) 2006-01-15
TW200404532A (en) 2004-04-01
AR040792A1 (es) 2005-04-20
RU2005102836A (ru) 2005-08-10
MXPA05001430A (es) 2005-06-06
CN1674908A (zh) 2005-09-28
BR0313470A (pt) 2005-06-21
JP2005538129A (ja) 2005-12-15
WO2004014386A1 (en) 2004-02-19
PL375414A1 (en) 2005-11-28
US20040067942A1 (en) 2004-04-08
EP1549320A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
PT871468E (pt) Metodos para tratar cancro da prostata com antagonistas de lhrh
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
TW200501960A (en) Synergistic kits and compositions for treating cancer
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
NO20082907L (no) Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
BR0116575A (pt) Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20005448L (no) Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert på patologisk celleproliferering
NO20032759D0 (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som SDSI/CHK2-inhibitorerog adjuvanter ved kjemoterapi eller strålingsterapi ved behandlingav kreft
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
BR112023012301A2 (pt) Combinações farmacêuticas que compreendem um inibidor de kras g12c e usos de um inibidor de kras g12c para o tratamento de cânceres
CY1106800T1 (el) Μεθοδοι και συνθεσεις δια χρησιμοποιησεως μεταβολιτων τepφεναδινης εν συνδυασμω μετ’ αναστολεων λευκοτριενιου